Monte Rosa Therapeutics (GLUE) Competitors $4.83 -0.05 (-1.02%) Closing price 04:00 PM EasternExtended Trading$4.74 -0.09 (-1.97%) As of 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLUE vs. CVAC, NTLA, CALT, HROW, PRAX, PAHC, PHVS, SYRE, GPCR, and AVDLShould you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include CureVac (CVAC), Intellia Therapeutics (NTLA), Calliditas Therapeutics AB (publ) (CALT), Harrow (HROW), Praxis Precision Medicines (PRAX), Phibro Animal Health (PAHC), Pharvaris (PHVS), Spyre Therapeutics (SYRE), Structure Therapeutics (GPCR), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical products" industry. Monte Rosa Therapeutics vs. Its Competitors CureVac Intellia Therapeutics Calliditas Therapeutics AB (publ) Harrow Praxis Precision Medicines Phibro Animal Health Pharvaris Spyre Therapeutics Structure Therapeutics Avadel Pharmaceuticals Monte Rosa Therapeutics (NASDAQ:GLUE) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability. Which has higher earnings and valuation, GLUE or CVAC? CureVac has higher revenue and earnings than Monte Rosa Therapeutics. CureVac is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$75.62M3.93-$72.70M$0.0860.38CureVac$579.18M2.12$175.50M$0.925.95 Which has more volatility & risk, GLUE or CVAC? Monte Rosa Therapeutics has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Comparatively, CureVac has a beta of 2.53, suggesting that its share price is 153% more volatile than the S&P 500. Do analysts recommend GLUE or CVAC? Monte Rosa Therapeutics currently has a consensus target price of $15.33, indicating a potential upside of 217.46%. CureVac has a consensus target price of $6.83, indicating a potential upside of 24.92%. Given Monte Rosa Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Monte Rosa Therapeutics is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67CureVac 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Is GLUE or CVAC more profitable? CureVac has a net margin of 35.44% compared to Monte Rosa Therapeutics' net margin of 3.86%. CureVac's return on equity of 30.89% beat Monte Rosa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa Therapeutics3.86% 2.65% 1.65% CureVac 35.44%30.89%25.54% Does the media refer more to GLUE or CVAC? In the previous week, CureVac had 1 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 1 mentions for CureVac and 0 mentions for Monte Rosa Therapeutics. CureVac's average media sentiment score of 1.79 beat Monte Rosa Therapeutics' score of 0.00 indicating that CureVac is being referred to more favorably in the news media. Company Overall Sentiment Monte Rosa Therapeutics Neutral CureVac Very Positive Do institutionals and insiders believe in GLUE or CVAC? 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 17.3% of CureVac shares are held by institutional investors. 6.5% of Monte Rosa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryCureVac beats Monte Rosa Therapeutics on 9 of the 16 factors compared between the two stocks. Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLUE vs. The Competition Export to ExcelMetricMonte Rosa TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$300.17M$3.07B$5.59B$9.54BDividend YieldN/A2.41%4.73%4.13%P/E Ratio60.3817.5328.9123.88Price / Sales3.93314.01445.9598.86Price / CashN/A42.6035.6858.35Price / Book1.337.828.165.60Net Income-$72.70M-$54.52M$3.25B$265.26M7 Day Performance-8.17%2.07%0.45%-1.00%1 Month Performance-4.26%17.29%8.27%6.09%1 Year Performance29.14%14.95%30.29%23.81% Monte Rosa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLUEMonte Rosa Therapeutics1.2665 of 5 stars$4.83-1.0%$15.33+217.5%+21.7%$300.17M$75.62M60.3890CVACCureVac4.0381 of 5 stars$5.39-0.6%$6.83+26.8%+58.3%$1.21B$579.18M5.86880Positive NewsNTLAIntellia Therapeutics4.595 of 5 stars$11.64-5.6%$33.37+186.7%-49.2%$1.21B$45.57M-2.23600Upcoming EarningsCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180HROWHarrow2.4715 of 5 stars$31.76-2.8%$63.83+101.0%+41.6%$1.17B$199.61M-56.71180Upcoming EarningsPRAXPraxis Precision Medicines1.8624 of 5 stars$54.22-4.2%$94.11+73.6%-10.0%$1.10B$8.55M-5.06110Trending NewsEarnings ReportAnalyst ForecastGap UpPAHCPhibro Animal Health4.2491 of 5 stars$26.50-5.1%$24.40-7.9%+53.0%$1.07B$1.19B33.971,940Positive NewsDividend AnnouncementPHVSPharvaris1.9898 of 5 stars$19.88+0.5%$36.20+82.1%+31.3%$1.04BN/A-6.6030Positive NewsSYRESpyre Therapeutics2.195 of 5 stars$16.97-1.9%$53.40+214.7%-38.3%$1.02B$890K-4.5073News CoverageEarnings ReportUpcoming EarningsGPCRStructure Therapeutics2.0583 of 5 stars$17.80-0.2%$76.17+327.9%-53.2%$1.02BN/A-20.46136News CoverageUpcoming EarningsAVDLAvadel Pharmaceuticals2.6916 of 5 stars$10.51-1.8%$18.33+74.4%-31.0%$1.02B$169.12M-38.9370Positive NewsUpcoming Earnings Related Companies and Tools Related Companies CVAC Alternatives NTLA Alternatives CALT Alternatives HROW Alternatives PRAX Alternatives PAHC Alternatives PHVS Alternatives SYRE Alternatives GPCR Alternatives AVDL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLUE) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GLUE Stock Alerts